PKC412 is an anti-metastatic and anticancer chemotherapeutic staurosporine derivative that inhibits FMS-like tyrosine kinase 3 (FLT3) and is currently in clinical trials as a potential treatment for acute myelogenous leukemia (AML). PKC412 also inhibits PKC. In keloid-derived fibroblasts, PKC412 increases activity of caspase 3, inducing apoptosis. In animal models of melanoma, PKC412 inhibits metastasis and platelet-aggregating activity. This compound also alters differentiation patterns of dendritic cells ex vivo.